Quantum Genomics (OTCMKTS:QNNTF – Get Free Report) and TELA Bio (NASDAQ:TELA – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations.
Earnings and Valuation
This table compares Quantum Genomics and TELA Bio”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quantum Genomics | N/A | N/A | N/A | N/A | N/A |
| TELA Bio | $69.30 million | 0.51 | -$37.84 million | ($0.89) | -0.98 |
Insider & Institutional Ownership
94.4% of TELA Bio shares are held by institutional investors. 4.7% of TELA Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Quantum Genomics and TELA Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quantum Genomics | 0 | 0 | 0 | 0 | 0.00 |
| TELA Bio | 1 | 1 | 3 | 0 | 2.40 |
TELA Bio has a consensus price target of $3.25, suggesting a potential upside of 274.38%. Given TELA Bio’s stronger consensus rating and higher possible upside, analysts clearly believe TELA Bio is more favorable than Quantum Genomics.
Volatility and Risk
Quantum Genomics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, TELA Bio has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.
Profitability
This table compares Quantum Genomics and TELA Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quantum Genomics | N/A | N/A | N/A |
| TELA Bio | -50.61% | -272.13% | -53.25% |
Summary
TELA Bio beats Quantum Genomics on 7 of the 10 factors compared between the two stocks.
About Quantum Genomics
Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs. The company also is involved in the development of drugs for the treatment of high blood pressure as monotherapy and the prevention, as well as treatment of heart failure. Quantum Genomics Société Anonyme was incorporated in 2005 and is based in Paris, France.
About TELA Bio
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Receive News & Ratings for Quantum Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
